What if death was not the end? What if, instead of saying our final goodbyes to loved ones, we could freeze their bodies and bring them back to life once medical technology has advanced enough to cure their fatal illnesses? This is the mission of Tomorrow Biostasis, a Berlin-based startup that specializes in cryopreservation.
Cryopreservation, also known as biostasis or cryonics, is the process of preserving a human body (or brain) in a state of suspended animation, with the hope that it can be revived in the future when medical technology has advanced enough to treat the original cause of death. This may seem like science fiction, but it is a legitimate scientific procedure, and Tomorrow Biostasis is one of the few companies in the world that offers this service.
Dr Emil Kendziorra, co-founder and CEO of Tomorrow Biostasis explained that the goal of cryopreservation is to extend life by preserving the body until a cure can be found for the original illness. He emphasized that cryopreservation is not a form of immortality, but rather a way to give people a second chance at life.
There’s a tiny, slow-burning ‘fuse’ attached to the ends of all our chromosomes, and as we naturally age, each of our cells loses more and more of that life-giving line.
Researchers in South Korea have now shown this fuse, known as the telomere, is unusually short in the cells of elderly people who are relatively healthy but have noticed early signs of depressive symptoms and cognitive decline, such as memory loss.
The randomized controlled trial presents more evidence for the telomere hypothesis of aging, which posits that all cells hit a point where they can no longer divide and replicate.
“That’s got molecules in it that will prevent cancer, among other things” like anti-inflammatory properties, he said. Some older research has shown, for example, that green tea consumption might be linked to a lower risk of stomach cancer.
Sinclair also said he takes supplements (like those sold on the Tally Health website) that contain resveratrol, which his team’s research has shown can extend the lifespan of organisms like yeast and worms.
While the compound, famously found in red wine, is known to have anti-inflammatory, anti-cancer, heart health, and brain health benefits, the research is mixed on if or how well such benefits can be achieved in humans through a pill.
Futurist Ray Kurzweil is still making waves years after his initial singularity claims as artificial intelligence continues to progress. With singularity milestones coming, Kurzweil believes immortality is achievable by 2030. Kurzweil’s predictions are met with a healthy dose of skepticism. A new video from the YouTube channel Adagio revisits futurist Ray Kurzweil’s ideas about how for humans, both singularity and immortality are shockingly imminent—as in, potentially just seven years away.
Loyal, a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs, has announced it has received protocol concurrence from the FDA for its companion dog longevity study.
Longevity. Technology: Loyal is on a mission is to help dogs everywhere live longer, healthier lives – and that means taking on the development of the first FDA-approved drugs explicitly intended to extend lifespan and healthspan. On the path to FDA approval, Loyal must run a clinical trial that objectively and robustly demonstrates that its drug extends dogs’ healthy lifespan – and does so safely. However, no-one has developed a dog – or human – longevity drug before, so Loyal is building the path to FDA approval largely from scratch.
Today, Loyal has announced that last week it learned from the FDA that the company has received protocol concurrence for its companion dog longevity study. This is good news for the longevity biotech sector, especially welcome as it comes on the same day that tech lender Silicon Valley Bank collapsed and was put under the control of the US Federal Deposit Insurance Corporation – news that left biotechs and VCs reeling.